Publications by authors named "Anton Glueck"
Article Synopsis
- - Secukinumab, an anti-IL-17A monoclonal antibody, shows significant improvement in psoriasis by 12 weeks, but its long-term molecular effects on inflammation were previously unclear.
- - A 52-week study revealed that patients treated with secukinumab continued to show histological and transcriptomic improvements in psoriatic lesions, with 14 out of 24 patients achieving significant clinical response (≥ 75% improvement).
- - Analysis of skin biopsies indicated that while some genomic profiles of responders improved, they only partially overlapped at different time points; distinct transcript subsets were identified that showed unique expression patterns, suggesting mechanisms driving disease resolution.
Background: Hyperactivity of the IL-23/IL-17 axis is central to plaque psoriasis pathogenesis. Secukinumab, a fully human mAb that selectively inhibits IL-17A, is approved for treatment of psoriasis, psoriatic arthritis, and ankylosing spondylitis. Secukinumab improves the complete spectrum of psoriasis manifestations, with durable clinical responses beyond 5 years of treatment.
View Article and Find Full Text PDF